Canaccord Genuity analyst Whitney Ijem maintained a Buy rating on Passage Bio (PASG – Research Report) yesterday and set a price target ...
PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) this week reported its third quarter financial results for 2024, ...
Mike Novogratz views a US Bitcoin Reserve as unlikely, citing limited Senate support. Polymarket also rates odds low for a quick passage.
Passage Bio, Inc. ( (PASG)) has released its Q3 earnings. Here is a breakdown of the information Passage Bio, Inc. presented to its investors. Passage Bio, Inc. is a clinical-stage genetic medicines ...
PHILADELPHIA , Nov. 06, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases ...
Latin Times on MSN3d
Incoming Republican Senate Intelligence Chair Once Called for Journalists to Be Prosecuted for EspionageBack in 2006, Tom Cotton said three NYT journalists had violated "espionage laws" for publishing a piece that detailed a ...
Ongoing patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline results ...
Season 3 of Celebrity Jeopardy! premieres on Wednesday, January 8, at 9 p.m. on ABC and on Hulu. The official announcement ...
Opus Genetics Inc (IRD) is expected to report $-0.33 for 3Q. Passage Bio Inc (PASG) is expected to report $-0.23 for 3Q. Pieris Pharmaceuticals Inc (PIRS) is expected to report for 3Q. Reliv ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback